All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
On June 18, 2021, it was announced that the European Commission (EC) granted full marketing authorization for azacitidine tablets (CC-486) as a maintenance therapy in adult patients with acute myeloid leukemia (AML). This includes patients who have achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not eligible for, or choose not to proceed to, hematopoietic stem cell transplantation.1
This European Commission marketing authorization approval is valid in all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway. It follows the Committee for Medicinal Products for Human Use (CHMP) recommendation and the approval by the U.S. Food and Drug Administration (FDA).
The approvals are based on results from the phase III QUAZAR AML-001 international, randomized, double-blind trial investigating CC‑486 maintenance versus placebo in patients aged ≥55 years and with newly diagnosed AML. Study participants had intermediate or poor cytogenetics.
Should all elderly patients with AML receive azacitidine as post-remission therapy?
At ASH 2019, Esther Natalie Oliva explains that based on the results of the trial comparing subcutaneous azacitidine with best supportive care, there is no clear...
SOHO 2019 | What is the role of maintenance therapy for patients with AML?
During SOHO 2019, Houston, US, the AML Global Portal were pleased to speak to Prof Selina M. Luger about the role of maintenance therapy for patients with AML.
Subscribe to get the best content related to AML delivered to your inbox